Overview

Use of CXCL9 as a Biomarker of Acthar Efficacy

Status:
Not yet recruiting

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).

Phase:

Phase 4

Details

Lead Sponsor:

University of California, San Francisco

Collaborator:

Mallinckrodt

Treatments:

Adrenocorticotropic Hormone